Company intelligence / Profile preview

Psirenity

Toronto, Ontario, Canada

Ownership: Private
Development stage: Other

Overview

Psirenity has been granted approval to conduct Jamaica’s first psilocybin clinical trial for managing depression, using immediate-release and controlled-release psilocybin, characterized as a Phase 2 study, with plans for a subsequent Phase 2 trial in an orphan CNS indication.[1][4]

Therapeutic areas: PsychiatryNeurology
Modalities: Small moleculeNutraceuticalNon-pharmacological therapy
Industry: Biotech

Partnerships

Scientific Research Council of Jamaica (SRC) – two-year partnership for cooperative studies and clinical work on psilocybin mushrooms and brain health, including cultivation and R&D support.[2]New Leaf Canada – upstream supply, facility, and research support relationship enabling psilocybin research in Canada and Jamaica.[2][8]

Beyond the preview

Go deeper on Psirenity.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Psirenity.

Explore the full profile